Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases. In addition, it develops BHV-3500 for the acute treatment and prevention of migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. The company was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSE:BHVN
Previous SymbolNASDAQ:BHVN
CUSIPN/A
Phone203-404-0410
Debt
Debt-to-Equity RatioN/A
Current Ratio11.99
Quick Ratio11.99
Price-To-Earnings
Trailing P/E Ratio-6.55
Forward P/E Ratio-5.56
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.66 per share
Price / Book8.95
Profitability
EPS (Most Recent Fiscal Year)($5.00)
Net Income$-127,190,000.00
Net MarginsN/A
Return on Equity-200.98%
Return on Assets-120.59%
Miscellaneous
Employees42
Outstanding Shares40,330,000
Market Cap$1.41 billion
OptionableOptionable
Biohaven Pharmaceutical (NYSE:BHVN) Frequently Asked Questions
What is Biohaven Pharmaceutical's stock symbol?
Biohaven Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHVN."
How were Biohaven Pharmaceutical's earnings last quarter?
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced its quarterly earnings data on Wednesday, November, 14th. The company reported ($1.53) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.05) by $0.48. View Biohaven Pharmaceutical's Earnings History.
When is Biohaven Pharmaceutical's next earnings date?
What price target have analysts set for BHVN?
9 brokerages have issued 12-month price targets for Biohaven Pharmaceutical's shares. Their predictions range from $40.00 to $65.00. On average, they expect Biohaven Pharmaceutical's share price to reach $51.3750 in the next year. This suggests a possible upside of 56.8% from the stock's current price. View Analyst Price Targets for Biohaven Pharmaceutical.
What is the consensus analysts' recommendation for Biohaven Pharmaceutical?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biohaven Pharmaceutical in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biohaven Pharmaceutical.
What are Wall Street analysts saying about Biohaven Pharmaceutical stock?
Here are some recent quotes from research analysts about Biohaven Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company's pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. " (10/16/2018)
- 2. Cantor Fitzgerald analysts commented, ". We recently hosted Biohaven for several investor meetings and came away with enhanced conviction in our nuanced perspectives on value creation over the next 12 months and beyond. Based on our recent due diligence, we believe a market inefficiency exists on the potential for rimegepant to usher- in a new treatment paradigm for not only acute, but also preventative treatment of migraine, irrespective if it’s first or second to market within the oral anti-CGRP class. Additionally, our investor conversations suggest that the troriluzole-led rest- of-pipeline (ROP) remains underappreciated, but this may change with increasingly visible clinical execution and 2H19 data." (10/12/2018)
- 3. Canaccord Genuity analysts commented, "We are updating our BHVN model after the company recently reported its 2Q18 results and filed its 10-Q. We are not making any substantial changes to our model and are maintaining our DCF-based price target at $43, which represents ~20% upside potential from current levels. As we noted recently (see here), we believe the pullback from recent highs affords an opportunity to buy the stock ahead of upcoming data-related events in 4Q18." (8/17/2018)
- 4. Needham & Company LLC analysts commented, "Biohaven reported 2Q18 financial results this wk and we spoke w/ mgmt for update. Biohaven announced encouraging results from BHV-0223 Phase 2 trial in Anxiety and plans to bring related drug troriluzole forward in a registration trial in both this indication and Spinocerebellar Ataxia by YE18. Enrollment has been completed in Phase 3 trial of ODT formulation of lead asset rimegepant in Acute Migraine and results expected 4Q18. Rimegepant open label Phase 3 safety trial has reached 1600 pts and mgmt reiterated guidance for interim analysis 4Q18. NDA submission in Acute Migraine probably mid-2019. Phase 3 rimegepant trial initiation in Chronic Migraine on track 4Q18. We continue to believe rimegepant will be an attractive option for both Acute and Chronic Migraine. Rest of pipeline higher risk, but still underappreciated." (8/17/2018)
Has Biohaven Pharmaceutical been receiving favorable news coverage?
News articles about BHVN stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biohaven Pharmaceutical earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.
Who are some of Biohaven Pharmaceutical's key competitors?
Some companies that are related to Biohaven Pharmaceutical include Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), SAGE Therapeutics (SAGE), Amarin (AMRN), United Therapeutics (UTHR), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP), Emergent Biosolutions (EBS), Array Biopharma (ARRY) and FibroGen (FGEN).
Who are Biohaven Pharmaceutical's key executives?
Biohaven Pharmaceutical's management team includes the folowing people:
- Dr. Vladimir Coric, CEO & Director (Age 47)
- Mr. James Engelhart, Chief Financial Officer (Age 54)
- Dr. Charles Conway, Chief Scientific Officer (Age 56)
- Dr. Robert Berman, Chief Medical Officer (Age 55)
- Mr. John Tilton, Chief Commercial Officer (Age 50)
When did Biohaven Pharmaceutical IPO?
(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital served as the underwriters for the IPO and William Blair and Needham & Company were co-managers.
Who are Biohaven Pharmaceutical's major shareholders?
Biohaven Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (8.31%), BlackRock Inc. (5.40%), Alliancebernstein L.P. (3.95%), JPMorgan Chase & Co. (3.82%), JPMorgan Chase & Co. (3.82%) and Eagle Asset Management Inc. (2.50%). Company insiders that own Biohaven Pharmaceutical stock include Albert Cha, Declan Doogan, Gregory Bailey, James Engelhart, John Tilton, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Institutional Ownership Trends for Biohaven Pharmaceutical.
Which major investors are selling Biohaven Pharmaceutical stock?
BHVN stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, FMR LLC, Alliancebernstein L.P., Russell Investments Group Ltd., Eagle Asset Management Inc., Virtus ETF Advisers LLC, Jane Street Group LLC and Bank of New York Mellon Corp. Company insiders that have sold Biohaven Pharmaceutical company stock in the last year include Declan Doogan, Gregory Bailey, James Engelhart, Kimberly Gentile, Portage Biotech Inc, Robert Berman and Vlad Coric. View Insider Buying and Selling for Biohaven Pharmaceutical.
Which major investors are buying Biohaven Pharmaceutical stock?
BHVN stock was bought by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Candriam Luxembourg S.C.A., Emerald Advisers Inc. PA, Sofinnova Ventures Inc, Emerald Mutual Fund Advisers Trust, JPMorgan Chase & Co., JPMorgan Chase & Co. and BlackRock Inc.. Company insiders that have bought Biohaven Pharmaceutical stock in the last two years include Albert Cha, James Engelhart and Robert Berman. View Insider Buying and Selling for Biohaven Pharmaceutical.
How do I buy shares of Biohaven Pharmaceutical?
Shares of BHVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biohaven Pharmaceutical's stock price today?
One share of BHVN stock can currently be purchased for approximately $32.76.
How big of a company is Biohaven Pharmaceutical?
Biohaven Pharmaceutical has a market capitalization of $1.41 billion. The company earns $-127,190,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Biohaven Pharmaceutical employs 42 workers across the globe.
What is Biohaven Pharmaceutical's official website?
How can I contact Biohaven Pharmaceutical?
Biohaven Pharmaceutical's mailing address is 215 CHURCH STREET, NEW HAVEN CT, 06510. The company can be reached via phone at 203-404-0410.
MarketBeat Community Rating for Biohaven Pharmaceutical (NYSE BHVN)
MarketBeat's community ratings are surveys of what our community members think about Biohaven Pharmaceutical and other stocks. Vote "Outperform" if you believe BHVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BHVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
